RU2483710C1 - Complex medication for treating dogs and cats with cutaneous mycoses, bacterioses and acaroses - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary, namely to veterinary mycology, bacteriology and parasitology. Complex medication for treating dogs and cats with cutaneous mycoses, bacterioses and acaroses includes as active and auxiliary components (wt %): chlorhexidine digluconate - 0.05-0.075; cypermethrin - 10.0-15.0; tetramethrin - 1.5-2.25; pyperonyl butoxide - 10.0-15.0; dimethyl sulfoxide - 15.0-22.5; polyethylene glycol M-200 or M 400 - 10.0-15.0; glycerol - 10.0-15.0, 1,2-propylene glycol - the remaining part.

EFFECT: medication has complex effect, without staining skin and its derivatives, is easily washed away with water, is efficient at temperature from minus 30 to plus 30°C and higher, has 2-year long storage term.

9 ex

Description

The invention relates to the field of veterinary mycology, bacteriology and parasitology, in particular to the preparation of an external preparation for the treatment of mycoses (dermatomycoses, candidiasis, malassesiosis), bacterioses (streptococcosis, staphylococcosis) and dog acaroses (sarcoptosis, notohedrosis, otodectosis, osodecodosis, and kodeodectosis) , notoedrosis).

Drugs are known for the treatment of animals sick with cutaneous mycoses, bacterioses and acaroses with various monoantimycotics, monoantiseptics, monoacaricides and only in the last 15 years have complex preparations begun to appear.

Known integrated drug for external use ointment "NM-BK", intended for external treatment of animals sick with dermatomycosis, bacteriosis and acarosis. Ointment "NM-BK" obtained by mechanical mixing of its constituent components (in wt.%):

salicylic or acetylsalicylic acid 7.8-11.0;

zinc oxide or magnesium oxide 7.8-11.0;

sulfur 10.0-11.0;

tar 5.0-6.0;

lysol or creolin phenol-free coal, or carbolic acid 2.5-3.0;

anhydrous lanolin 17.5-19.0;

water 7.5-8.5;

turpentine 2.0-2.5;

petroleum jelly - the rest.

A method of treating animals consists in applying a thin layer of ointment to the affected [1] area of the skin and 2-4 cm around it with light rubbing into the treated surface.

Also known is a complex external preparation "Ointment for the treatment of fungal and tick-borne skin lesions of the animal" AKAROBOR ". The drug includes sulfur, diphenhydramine, dioxidine and a filler. Additionally, it contains aquabor and methyluracil, and Arctic fox fat is used as a filler in the following ratio of components (in wt.%):

aquabor - 20.0-40.0;

diphenhydramine - 07.1.5;

methyluracil - 2.0-4.0;

sulfur - 3.0-6.0;

Arctic fox fat - 40.0-80.0.

The proposed ointment, according to the authors, has high therapeutic efficacy, a wide range of fungicidal, acaricidal, antimicrobial effects, is a low toxic and environmentally friendly drug. Shelf life - 6 months.

The method of application of the AKAROBOR ointment consists in applying it in a thin layer to the affected skin of the animal with a gauze swab and rubbing it lightly once every 3-4 days in the summer season. Processing is carried out 3-5 times [2]. PROTOTYPE.

+ The objectives of our research were to obtain a complex preparation for the treatment of patients with dermatomycosis (trichophytosis, microsporosis), skin candidiasis and malassesiosis, staphylococcosis and streptococcosis of dogs and cats, sarcoptosis, notohedrosis, high otodectosis, and erydecododecodosis - with catodecosis - treatment effectiveness.

The proposed drug against dermatomycosis, cutaneous candidiasis and malassesiosis, staphylococcosis and streptococcosis of dogs and cats, sarcoptosis, notedrosis, otodectosis and demodecosis of dogs, otodectosis and notedosis of cats, including (wt.%):

chlorhexidine bigluconate (HGBG) - 0.05-0.075;

cypermethrin - 10.0-15.0;

tetramethrin - 1.5-2.25;

piperonyl butoxide (PPB) - 10.0-15.0;

dimethyl sulfoxide (DMSO) - 15.0-22.5;

polyethylene glycol (PEG) M-200 or M 400 - 10.0-15.0;

glycerin - 10.0-15.0;

1,2-propylene glycol - the rest.

HGBG - has a pronounced bactericidal and mycocidal effect. Cypermethrin, tetramethrin, piperonyl butoxide - have a pronounced acaripid effect in the association. DMSO - has a high transport ability of active substances through the skin layers to the basement membrane, antimicrobial activity, anti-inflammatory, weak local anesthetic, analgesic and moderate fibrinolytic effect. PEG M-200 or M-400 creates a prolonged effect. Glycerin - has emollient and mild irritant effects. 1,2-propylene glycol - is used as a solvent of active substances and auxiliary components, which also has microbostatic activity.

The drug in appearance is a colorless transparent liquid, slightly viscous consistency, does not stain the skin and its derivatives, is easily washed off with water. Store it at a temperature of minus 30 to plus 30 ° C. Shelf life is 2 years. The drug is effective in the storage temperature range.

A method of manufacturing a preparation against cutaneous mycoses, bacterioses, as well as dog and cat acaroses, consists in the following:

- DMSO and PEG M 200 or M 400 in calculated quantities are placed in the mixer tank, mix thoroughly for 5 minutes at 300-600 rpm;

- in the resulting mixture add in the calculated amount of chlorhexidine bigluconate and mix in the same mode:

- cypermethrin, tetramethrin and PPB are added to the mixture in the calculated amounts, mixed in the same mode;

- 1,2-propylene glycol in the calculated amount is added to the resulting mixture and stirred in the same mode;

- the resulting preparation is packaged and labeled.

A method of treating dogs and cats with skin mycoses, bacterioses and acaroses consists in applying the drug to the affected areas with a coverage of 1-2 cm along the periphery of healthy skin once a day for mycoses and bacterioses, and once every 5-10 days for acaroses until recovery.

We present 2 variants of the drug with different contents of active substances and auxiliary components in wt.%:

Option 1.

The composition of the drug:

chlorhexidine bigluconate (HGBG) - 0.05;

cypermethrin - 10;

tetramethrin - 1.5;

piperonyl butoxide (PPB) - 10.0;

dimethyl sulfoxide (DMSO) - 15.0;

polyethylene glycol (PEG) M-200 or M 400 - 10.0;

glycerin - 10.0;

1,2-propylene glycol - the rest.

Example 1. The drug was used for therapeutic purposes in patients with trichophytosis of 3 dogs and 5 cats, as well as in 5 dogs and 11 cats with microsporosis in the Vetklinik Center in Rostov-on-Don. The drug was applied 1 time per day for 3 days to lesions with a coverage of 1 cm of healthy skin on the periphery. After 3 days, pathological material was selected from the lesion sites and plated on fungal culture media. The growth of fungi was not found, which indicated the high effectiveness of the drug and method of treatment. Observation of treated animals was carried out for 30 days. Manifestations of dermatomycosis in the former mycotic foci are not registered. They were first cleansed of crusts and dandruff, and then overgrown with healthy hair. Complications during the treatment and after are not registered.

Example 2. The drug was also tested on 7 dogs and 3 cats with cutaneous candidiasis in the Don Dog Training Center "DonKPTS" Rostov-on-Don. Foci of candidal lesion were treated as described above, but within 5 days, since fungi of the genus Candida are more resistant to antimycotics than dermatomycetes. Mycological studies of pathological material from the treated lesions of the fungus cultures could not be identified, which indicates a high therapeutic efficacy of the drug and the treatment method. Within 30 days of monitoring the treated animals, there were no manifestations of candidiasis in the former mycotic foci. They first cleared of crusts, and then overgrown with healthy hair. No medical complications have been reported.

Example 3. The drug was also used for malaysia otitis in 6 dogs and 2 cats in the Don Dog Training Center "DonKPTS" Rostov-on-Don. The cavity of the auricles was treated as described above for 5 days, since the yeast-like fungi of the genus Malassezia are resistant to antimycotics. Mycological studies of pathological material from the treated auditory canal of the fungus could not be distinguished, which indicated a high therapeutic efficacy of the drug and the treatment method. Within 30 days of monitoring the treated animals, no re-manifestation of malassesiosis was recorded. The ear canals cleared of crusts, and the skin was restored. No medical complications have been reported.

Example 4. The drug was used in 5 dogs and 2 cats suffering from cutaneous staphylococcosis in the veterinary clinic VIEV. The lesions were treated as described above for 5 days. It was not possible to isolate bacteriological studies of pathological material from the treated lesions of bacterial cultures, indicating a high therapeutic efficacy of the drug and the treatment method. Within 30 days of monitoring the treated animals, the manifestations of staphylococcosis in the former foci were not recorded. They first cleared of crusts, and then overgrown with healthy hair. No medical complications have been reported.

Example 5. The drug was used in 3 dogs and 3 cats with cutaneous streptococcosis in the veterinary clinic VIEV. The lesions were treated as described above for 5 days. It was not possible to isolate bacteriological studies of pathological material from the treated lesions of bacterial cultures, indicating a high therapeutic efficacy of the drug and the treatment method. Within 30 days of monitoring the treated animals, there were no manifestations of streptococcosis in the former foci. They first cleared of crusts, and then overgrown with healthy hair. No medical complications have been reported.

Example 6. The drug was also tested at stages 1 and 2 of demodicosis in 10 dogs in the Don Dog Training Center "DonKPTS" and Vetklinik "Center" in Rostov-on-Don, as well as in 1 dog in SBBZH, South-Western Administrative District of Moscow. Processed lesion sites 1 time in 5 days 3 times. 15 days after the first treatment, deep ticks of the skin from the former lesions of live ticks were not found, which indicated the effectiveness of the drug and the treatment method. No medical complications have been reported.

Example 7. The drug was used for otodhetosis in 4 cats in the Don Cynological Training Center "DonKPTs" in Rostov-on-Don, in 4 cats in the SBBZH of the South-Western Administrative District of Moscow and 3 cats in the Vetklinik "Center" in Rostov-on-Don. The drug was used, 0.5 ml of the drug in each ear 1 time in 7 days three times. 21 days after the first treatment, no live ticks were found in skin scrapings from the former lesion sites, which indicated the effectiveness of the drug and the treatment method. No medical complications have been reported.

Example 8. A preparation of the indicated composition was tested in case of notoedrosis of 3 dogs and 7 cats in the veterinary clinic of VIEV in Moscow. The drug was used once every 7 days three times by applying it to the affected area with a coverage of 1 cm of healthy skin around. 21 days after the first treatment, no live ticks were found in skin scrapings from the former lesion sites, which indicated the effectiveness of the drug and the treatment method. No medical complications have been reported.

Example 9. The drug was used for sarcoptosis in 5 dogs in the veterinary clinic VIEV Moscow. The drug was used once every 7 days three times by applying it to the affected area with a coverage of 1 cm of healthy skin around. 21 days after the first treatment, no live ticks were found in skin scrapings from the former lesion sites, which indicated the effectiveness of the drug and the treatment method. No medical complications have been reported.

When testing the first version of the drug, 39 dogs and 37 cats were used.

Option 2

chlorhexidine bigluconate (HGBG) - 0.075;

cypermethrin - 15.0;

tetramethrin - 2.25;

piperonyl butoxide (PPB) - 15.0;

dimethyl sulfoxide (DMSO) - 22.5;

polyethylene glycol (PEG) M-200 or M 400 - 15.0;

glycerin - 15.0;

1,2-propylene glycol - the rest.

The drug 2 variants of the composition was used for all these diseases in the same ways. Used 37 dogs and 33 cats. The results of treatment are positive, however, in 1 dog and 3 cats, after vomiting of the drug from the treated skin, vomiting was registered. Therefore, the preparation of option 1 is recommended for the manufacture and use in animals.

The proposed drug with positive results was tested in 2009-2010. in veterinary practice (veterinary clinics SBBZH, South-West Administrative District and VIEV of Moscow, “CENTER” of Rostov-on-Don, Don Dog Training Center “DonKPTS”) for 76 dogs and 70 cats.

The drug will be used in dog and feline breeding clubs, pedigree centers, kennels and shelters as an effective therapeutic agent for the treatment of dogs and cats with skin mycoses, bacterioses and acaroses.

Please assign the proposed drug the name Mikobakar-S, according to the approved documentation.

Information sources

1. RF patent No. 2107495 of 03/27/1998, class. A61K 33/00. Comprehensive external drug ointment "YM-BK."

2. RF patent No. 2030868 dated 09/27/1987, class. A01N 25/00, 1997. Ointment for the treatment of fungal and tick-borne skin lesions of the animal "AKAROBOR" [prototype].

3. Apanasenko, N.A. Specific therapy and prevention of cutaneous candidiasis of carnivores: Dis: ... cand. vet. Sciences: 06.02.02 / N.A. Apanasenko; VIEV. - M., 2010 .-- 196 p.

4. Ivchenko, O.V. Diagnosis of animal malaysesiosis: Dis: ... cand. vet. Sciences: 06.02.02 / O.V.Ivchenko; VIEV. - M., 2010 .-- 152 p.

5. Litvinov, A.M. Dermatophytosis of cats and dogs / Litvinov A.M. // Veterinary medicine. - 2000. - No. 11. S.51-53.

6. Parasitology and invasive animal diseases / M.Sh. Akbaev, F. I. Vasilevich, T. V. Balagula, N. K. Konovalov; Ed. M.Sh. Akbaeva. - M .: Kolos, 2001 .-- 528 p.

Claims (1)

A complex preparation for treating dogs and cats with skin mycoses, bacterioses and acaroses, characterized in that as active substances and auxiliary components it includes, wt.%:
chlorhexidine bigluconate 0.05-0.075 cypermethrin 10.0-15.0 tetramethrin 1.5-2.25 piperonyl butoxide 10.0-15.0 dimethyl sulfoxide 15.0-22.5 polyethylene glycol M-200 or M 400 10.0-15.0 glycerol 10.0-15.0 1,2-propylene glycol rest